BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 29951790)

  • 21. Postoperative upgrading of prostate cancer in men ≥75 years: a propensity score-matched analysis.
    Herlemann A; Buchner A; Kretschmer A; Apfelbeck M; Stief CG; Gratzke C; Tritschler S
    World J Urol; 2017 Oct; 35(10):1517-1524. PubMed ID: 28493044
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Survival after radical prostatectomy vs. radiation therapy in ductal carcinoma of the prostate.
    Chierigo F; Borghesi M; Würnschimmel C; Flammia RS; Horlemann B; Sorce G; Höh B; Tian Z; Saad F; Graefen M; Gallucci M; Briganti A; Montorsi F; Chun FKH; Shariat SF; Mantica G; Suardi N; Terrone C; Karakiewicz PI
    Int Urol Nephrol; 2022 Jan; 54(1):89-95. PubMed ID: 34797483
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predicting prostate cancer-specific outcome after radical prostatectomy among men with very high-risk cT3b/4 PCa: a multi-institutional outcome study of 266 patients.
    Moltzahn F; Karnes J; Gontero P; Kneitz B; Tombal B; Bader P; Briganti A; Montorsi F; Van Poppel H; Joniau S; Spahn M
    Prostate Cancer Prostatic Dis; 2015 Mar; 18(1):31-7. PubMed ID: 25535100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Survival after Radical Prostatectomy versus Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer.
    Chierigo F; Wenzel M; Würnschimmel C; Flammia RS; Horlemann B; Tian Z; Saad F; Chun FKH; Graefen M; Gallucci M; Shariat SF; Mantica G; Borghesi M; Suardi N; Terrone C; Karakiewicz PI
    J Urol; 2022 Feb; 207(2):375-384. PubMed ID: 34555930
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radical Prostatectomy or External Beam Radiation Therapy vs No Local Therapy for Survival Benefit in Metastatic Prostate Cancer: A SEER-Medicare Analysis.
    Satkunasivam R; Kim AE; Desai M; Nguyen MM; Quinn DI; Ballas L; Lewinger JP; Stern MC; Hamilton AS; Aron M; Gill IS
    J Urol; 2015 Aug; 194(2):378-85. PubMed ID: 25711194
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor characteristics, treatments, and oncological outcomes of prostate cancer in men aged ≤50 years: a population-based study.
    Pompe RS; Smith A; Bandini M; Marchioni M; Martel T; Preisser F; Leyh-Bannurah SR; Schiffmann J; Saad F; Huland H; Graefen M; Shariat SF; Tilki D; Karakiewicz PI
    Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):71-77. PubMed ID: 29339806
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identifying optimal candidates for local treatment of the primary tumor among patients diagnosed with metastatic prostate cancer: a SEER-based study.
    Fossati N; Trinh QD; Sammon J; Sood A; Larcher A; Sun M; Karakiewicz P; Guazzoni G; Montorsi F; Briganti A; Menon M; Abdollah F
    Eur Urol; 2015 Jan; 67(1):3-6. PubMed ID: 25217422
    [TBL] [Abstract][Full Text] [Related]  

  • 29. External Beam Radiation Therapy With a Brachytherapy Boost Versus Radical Prostatectomy in Gleason Pattern 5 Prostate Cancer: A Population-Based Cohort Study.
    Wang C; Kishan AU; Kamrava M; Steinberg ML; King CR
    Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1045-1052. PubMed ID: 28721887
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy.
    Kupelian PA; Elshaikh M; Reddy CA; Zippe C; Klein EA
    J Clin Oncol; 2002 Aug; 20(16):3376-85. PubMed ID: 12177097
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Survival outcomes of radical prostatectomy vs. external beam radiation therapy in prostate cancer patients with Gleason Score 9-10 at biopsy: A population-based analysis.
    Knipper S; Palumbo C; Pecoraro A; Rosiello G; Tian Z; Briganti A; Zorn KC; Saad F; Tilki D; Graefen M; Karakiewicz PI
    Urol Oncol; 2020 Mar; 38(3):79.e9-79.e14. PubMed ID: 31653563
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of age and comorbidities on long-term survival of patients with high-risk prostate cancer treated with radical prostatectomy: a multi-institutional competing-risks analysis.
    Briganti A; Spahn M; Joniau S; Gontero P; Bianchi M; Kneitz B; Chun FK; Sun M; Graefen M; Abdollah F; Marchioro G; Frohenberg D; Giona S; Frea B; Karakiewicz PI; Montorsi F; Van Poppel H; Jeffrey Karnes R;
    Eur Urol; 2013 Apr; 63(4):693-701. PubMed ID: 22959192
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study.
    Culp SH; Schellhammer PF; Williams MB
    Eur Urol; 2014 Jun; 65(6):1058-66. PubMed ID: 24290503
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cancer-specific survival after radical prostatectomy versus external beam radiotherapy in high-risk and very high-risk African American prostate cancer patients.
    Hoeh B; Würnschimmel C; Flammia RS; Horlemann B; Sorce G; Chierigo F; Tian Z; Saad F; Graefen M; Gallucci M; Briganti A; Terrone C; Shariat SF; Kluth LA; Mandel P; Chun FKH; Karakiewicz PI
    Prostate; 2022 Jan; 82(1):120-131. PubMed ID: 34662443
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cancer-specific mortality after radical prostatectomy vs external beam radiotherapy in high-risk Hispanic/Latino prostate cancer patients.
    Hoeh B; Hohenhorst JL; Flammia R; Horlemann B; Sorce G; Chierigo F; Tian Z; Saad F; Graefen M; Gallucci M; Briganti A; Terrone C; Shariat SF; Kluth LA; Becker A; Chun FKH; Karakiewicz PI
    Int Urol Nephrol; 2022 Jan; 54(1):81-87. PubMed ID: 34783982
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of initial local therapy on survival in men later receiving chemotherapy for prostate cancer: a population-based, propensity-weighted multivariable analysis.
    Zabell JR; Adejoro O; Jarosek SL; Elliott SP; Konety BR
    World J Urol; 2016 Oct; 34(10):1397-403. PubMed ID: 26914817
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Impact of Local Treatment on Overall Survival in Patients with Metastatic Prostate Cancer on Diagnosis: A National Cancer Data Base Analysis.
    Löppenberg B; Dalela D; Karabon P; Sood A; Sammon JD; Meyer CP; Sun M; Noldus J; Peabody JO; Trinh QD; Menon M; Abdollah F
    Eur Urol; 2017 Jul; 72(1):14-19. PubMed ID: 27174537
    [TBL] [Abstract][Full Text] [Related]  

  • 38. External beam radiation therapy improves survival in high- and intermediate-risk non-metastatic octogenarian prostate cancer patients.
    Knipper S; Dzyuba-Negrean C; Palumbo C; Pecoraro A; Rosiello G; Tian Z; Briganti A; Saad F; Tilki D; Graefen M; Karakiewicz PI
    Int Urol Nephrol; 2020 Jan; 52(1):59-66. PubMed ID: 31542882
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The effect of marital status on stage and survival of prostate cancer patients treated with radical prostatectomy: a population-based study.
    Abdollah F; Sun M; Thuret R; Abdo A; Morgan M; Jeldres C; Shariat SF; Perrotte P; Montorsi F; Karakiewicz PI
    Cancer Causes Control; 2011 Aug; 22(8):1085-95. PubMed ID: 21643929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rates of Positive Surgical Margins and Their Effect on Cancer-specific Mortality at Radical Prostatectomy for Patients With Clinically Localized Prostate Cancer.
    Preisser F; Mazzone E; Knipper S; Nazzani S; Bandini M; Shariat SF; Tian Z; Saad F; Montorsi F; Zorn KC; Graefen M; Tilki D; Karakiewicz PI
    Clin Genitourin Cancer; 2019 Feb; 17(1):e130-e139. PubMed ID: 30366880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.